Comparative clinical and economic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation
Download in PDFAim
Clinical and aconomic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation.
Material and methods
Modelling was used to evaluate cost-effectiveness and budget impact of phosphocreatine and levosimendan administration during cardiac surgey. Efficacy of two medication was compared by network meta-analysis.
Results
Perioperative phosphocreatine administration during extracorporeal circulation results in a lower risk of unfavorable outcomes including myocardial infarction, serious arrhythmias and inotropic requirement compared to the standard treatment, and is 42.8% cheaper compared to levosimendan administration.
Conclusion
Phosphocreatine administration during cardiac surgery is cost saving and more effective that levosimendan administration.
Key words
Pharmacoeconomics, budget impact analysis, cardiac protection, cardiac surgery, phosphocreatine.